Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-11-09

FDA Approved: REZUROCK — Supplemental Application (Kadmon Pharmaceuticals, LLC)

View source ↗

Summary

FDA approved a supplemental application for REZUROCK (belumosudil) from Kadmon Pharmaceuticals, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • REZUROCK (belumosudil)

Snippet

SUPPL AP for REZUROCK (BELUMOSUDIL)